GlassScriptPhysician profile
Harrison W Yoo
NPI 1083699243
$1,158.97
in general payments reported to CMS, 2019-2025
22 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $57.34 · 2023: $246 · 2024: $263 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.11 | 2023-2025 | Airsupra, Breztri |
| Abbott Laboratories | $179.09 | 2019-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $141.56 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Novo Nordisk INC | $59.62 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $55.84 | 2024-2025 | Jardiance, Mounjaro |
| Medtronic, INC. | $45.39 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $44.06 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $40.24 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $36.74 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $32.30 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $28.73 | 2019 | |
| Astellas Pharma US INC | $28.29 | 2023 | Veozah |
| Ultragenyx Pharmaceutical INC. | $24.60 | 2023 | |
| Inspire Medical Systems, INC. | $23.53 | 2024 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.42 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.67 | 2025 | |
| Esperion Therapeutics, INC. | $15.40 | 2025 | Nexletol |
| Vertiflex, INC. | $14.45 | 2019 | |
| Abbvie INC. | $14.19 | 2023 | Ubrelvy |
| Pfizer INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.